Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

September 30, 2000

Primary Completion Date

July 15, 2002

Study Completion Date

July 15, 2002

Conditions
Acromegaly
Interventions
DRUG

Lanreotide (Autogel formulation)

Trial Locations (17)

14033

Chu de la Cote de Nacre, Caen

21034

Hôpital du Bocage, Dijon

31403

Hôpital de Rangueil, Toulouse

33604

Hôpital du Haut-Levêque, Pessac

34059

Hôpital Lapeyronie, Montpellier

35056

Hôpital Sud, Rennes

42055

Hôpital Bellevue, Saint-Etienne

49033

Chu d'Angers, Angers

51092

Hôpital Maison Blanche, Reims

67098

Hôpital de Hautepierre, Strasbourg

69394

Hôpital Neurologique, Lyon

76233

Hôpital de Bois Guillaume, Bois-Guillaume

80054

Hôpital Sud, Amiens

87042

Hôpital du Cluzeau, Limoges

94270

Chu de Bicêtre, Le Kremlin-Bicêtre

06202

Hôpital de l'Archet 1, Nice

CH-1011

Centre Hospitalier Vaudois, Lausanne

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00210457 - Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients | Biotech Hunter | Biotech Hunter